Research finds that antibiotic may help in treatment of alcohol use disorder

November 15, 2016
To date, there are not particularly effective therapies for AUD, making the development of new therapies vital. Credit: TTUHSC

To date, there are not particularly effective therapies for AUD, with only three FDA approved drugs along with behavioral modification programs such as Alcoholics Anonymous. Together or alone, none are particularly effective and relapse is common, making the development of new therapies vital.

A collaborative effort between Texas Tech University Health Sciences Center (TTUHSC) researchers Susan Bergeson, Ph.D., Joseé Guindon, Ph.D., Peter Syapin, Ph.D., clinicians David Edwards, M.D., David Trotter, Ph.D., and Deborah Finn, Ph.D., at Oregon Health and Science University has identified a potential new treatment for AUD.

"Recent research has used new technologies to identify genes and pathways related to neuroinflammation as part of alcohol's action on addiction processes," said Bergeson, associate professor in the TTUHSC Department of Pharmacology and Neuroscience. "Minocycline, a tetracycline antibiotic normally used against bacterial infections, has known anti-inflammatory actions and recently was shown to reduce alcohol consumption."

In research described in four companion papers published by the journal Alcoholism: Clinical and Experimental Research, the teams first reported the screening of several tetracycline drugs to see if all were effective in reducing alcohol use. The results pointed to a specific structural component of the drugs as responsible for positive outcomes and led to the discovery that tigecycline, a minocycline analog, was highly effective in reducing binge and chronic consumption, in both dependent and non-dependent animals.

In addition, withdrawal seizures, which represent a medical emergency in humans, also were reduced in mice by tigecycline. Finally, binge drinking was shown to cause a persistent change in pain perception, which was reduced in males, but not females, by tigecycline. The Bergeson, Finn, Guindon and Syapin labs' research lead to the conclusion that tigecycline, already approved by the FDA for use in humans for Methicillin-resistant Staphylococcus aureus or MRSA infections, may be a good lead drug for the effective reduction of , withdrawal symptoms and pain.

"We have known that high levels of can cause damage to the liver and brain, but it has been more difficult to understand how AUD is cemented," said Bergeson. "Every person knows a family member or close friend that struggles with AUD, and now with these findings, a simple antibiotic that is already FDA approved could help."

Explore further: Team leads world-first new treatment for alcohol addictions

Related Stories

Recommended for you

Smokers' memories could help them quit

February 16, 2017

Rather than inciting fear, anti-smoking campaigns should tap into smokers' memories and tug at their heartstrings, finds a new study by Michigan State University researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.